FDA 483 - OraLabs, Incorporated - October 02, 2025

During an inspection conducted by the U.S. Food and Drug Administration from September 22 to October 2, 2025, OraLabs, Incorporated, an OTC drug manufacturer, was issued an FDA Form 483 citing significant observations regarding its operational and quality control practices. These observations suggest potential deviations from current Good Manufacturing Practices (cGMP), as mandated by the Federal Food, Drug and Cosmetic Act. Key violations highlighted include a failure to thoroughly investigate batches that did not meet microbiological specifications; specifically, 13 out of 15 batches with failed microbiological tests between 2023-2025 were shipped despite inconclusive investigations. The inspection also identified a lack of adequate written procedures for production and process controls, including the absence of microbiological testing for certain products. Furthermore, OraLabs failed to follow established cleaning and sanitizing procedures, with incomplete documentation for cleaning activities. Process validation for manufacturing equipment, such as mixing tanks, was found to be deficient due to compromised analytical studies. Equipment and utensils, including pots and lids, were not adequately cleaned and maintained, showing visible film and stains, and damaged lids compromised the integrity of raw material storage, posing contamination risks. Finally, the company lacked written cleaning procedures for in-process totes. To address these concerns, OraLabs, Incorporated is required to submit a robust response outlining specific corrective and preventive actions to ensure compliance with regulatory standards and safeguard the quality, purity, and safety of its drug products.